2024-517851-11-00RecruitingPhase 1
A prospective, single-center phase I pilot study to assess the tissue activity of multidrug resistance-associated protein 1 with positron emission tomography
Source: EU CTIS (euclinicaltrials.eu) · Last updated 17 Jan 2025 · Not updated for over 12 months - ask the site whether it is still open
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 26 Nov 2024
- Start date
- 5 Sept 2022
- Lead sponsor
- Medical University Of Vienna
- Diseases
- Alzheimer disease
- EU CT number
- 2024-517851-11-00
- EudraCT number
- 2021-006348-29
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 40
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for healthy volunteers and people with Alzheimer's disease. It studies the activity of multidrug resistance-associated protein 1 in tissue with positron emission tomography.
- Age
- 18 years or older
- Sex
- All sexes can join.
Read by machine on 9 Nov 2026.
Sites (1)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Medical University of Vienna | Vienna | Austria | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.